title: Vaccine Manufacturing--Second Annual visiongain Conference.
abstract: The Vaccine Manufacturing--Second Annual visiongain Conference, held in London, included topics covering new technological developments in the field of influenza vaccine research. This conference report highlights selected presentations on influenza vaccine development in mammalian, insect and avian embryonic cells, regulatory considerations for cell culture-based influenza vaccine production, an improved animal model for influenza infection, and considerations for designing vaccine manufacturing facilities. Investigational drugs discussed include FluBiovax (Immunobiology Ltd) and FluBlok (Protein Sciences Corp/UMN Pharma Inc).
authors.affiliation: Protein Sciences Corp, 1000 Research Parkway, Meriden, CT 06450, USA. cmcpherson@proteinsciences.com
authors.forename: Clifton
authors.initials: C
authors.lastname: McPherson
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence / Q000379:methods / Q000639:trends; D005289:Ferrets; D006801:Humans; D007252:Influenza Vaccines / Q000096:biosynthesis; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control; D013678:Technology, Pharmaceutical; D014612:Vaccines / Q000191:economics*
chemical_list: D007252:Influenza Vaccines; D014612:Vaccines